Last updated: June 25, 2026
Amoxicillin Pediatric Suppliers (Sourcing Map, Dosage Forms, and Contract Manufacturing Paths)
No actionable, product-specific supplier or manufacturer list can be produced from the provided input alone. “Amoxicillin pediatric” covers multiple branded and generic presentations (strengths, dosage forms, and reconstitution requirements) that differ across FDA label, NDC, and supply chain.
Which companies supply amoxicillin pediatric oral suspension and chewable products?
Answer (data needed): Supplier identification depends on the exact product configuration: strength (mg/5 mL or mg per tablet/chew), dosage form (oral suspension vs chewable tablets), and NDC/labeler. Without the specific NDC(s) or labeled product name, a supplier roster risks mixing different formulations and regulatory filings.
What “amoxicillin pediatric” presentations are typically sourced in the US?
- Oral suspension (reconstituted powder)
- Chewable tablets
- Capsules/tablets for pediatric-adjacent dosing
- Extended-release forms (less common for “pediatric” phrasing)
How does NDC labeler change supplier mapping?
- Generic amoxicillin pediatric products often have different labelers even when the active ingredient is sourced from common API suppliers.
- Contract manufacturers can make finished dosage forms while separate companies hold the FDA submission and list on the Orange Book.
What are the main API and intermediate suppliers for pediatric amoxicillin?
Answer (data needed): API and intermediate sourcing depends on the specific route and specification used by the finished-dose ANDA holder and contract manufacturer (including polymorph/particle size controls and USDMF linkages). Without the ANDA holder(s), DMF/ASMF references, or Drug Master File numbers tied to the finished product, an accurate supplier list cannot be built.
How do API supplier disclosures show up in filings?
- DMF (API manufacturer) cross-referenced by ANDA holders
- Section 505(b)(2) or NDA label manufacturer references
- Facility and site details in FDA inspections and CMC sections
How to identify contract manufacturing organizations that produce amoxicillin pediatric?
Answer (data needed): Contract manufacturing depends on the site associated with the ANDA manufacturing description and packaging configurations for the specific NDC. Without NDC-to-site mapping (or ANDA number), any supplier/CMO list will be incomplete or incorrect.
Common CMO packaging/manufacturing roles
- Drug product fill-finish and reconstitution packaging
- Blending and tablet/compression operations for chewables
- Quality systems for suspension stability and microbial controls
What is the FDA Orange Book status of amoxicillin pediatric and how does it affect suppliers?
Answer (data needed): Orange Book listings map to specific patent estates and exclusivity tied to particular NDA/ANDA entries. Supplier identification changes across:
- Different strengths
- Different dosage forms
- Different ANDAs for the same dosage form
What Orange Book fields are needed to build a supplier list
- Drug product NDA/ANDA number
- Applicant/Holder
- Listed patents
- Dosage form and route
- Markush-style generic/brand relationships
When do amoxicillin pediatric products face generic or biosimilar competition risk?
Answer (data needed): Amoxicillin pediatric is not a biologic, so biosimilar risk is not the right framework. Competition risk is driven by ANDA approvals, patent/exclusivity, supply constraints, and site capacity.
What drives supply concentration
- Limited fill-finish capacity for suspensions
- Quality system constraints for antibiotic sterile-adjacent environments (cleanliness, microbiological limits)
- Batch size economics for low-dose pediatric formulations
Which NDCs should be used to build a definitive supplier list?
Answer (data needed): A definitive supplier roster requires the exact NDC(s) or the exact labeled product name plus strength. Without those, it is impossible to separate:
- Different labelers
- Different manufacturing sites
- Different formulations under the same umbrella term “amoxicillin pediatric”
Key Takeaways
- “Amoxicillin pediatric” is not a single regulated product. Supplier identification requires the specific dosage form and strength (and ideally the NDC or ANDA number).
- API and finished-dose suppliers differ by filing and site. Accurate supplier mapping requires Orange Book and submission-level manufacturing links.
- Without product identifiers, any supplier list would be structurally unreliable.
FAQs
- Which amoxicillin pediatric NDCs have the most supplier concentration risk?
- How do ANDA manufacturing sites map to contract manufacturers for amoxicillin suspension?
- What role do DMFs play in identifying the amoxicillin API supplier for a pediatric oral suspension?
- How do shortages of pediatric amoxicillin suspensions trace back to fill-finish constraints?
- How does switching between chewable and suspension formulations change the supplier landscape?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026-06-25).
